Following CORDStrom TM, INmune Bio plans to transition production of INKmune ®, its NK-priming cell medicine for solid tumors, to the same facility, supporting ongoing and future trials in the US and ...

SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced that the United States Food ...

Chromatin Bioscience, a leader in the design of synthetic promoters and gene control systems, is pleased to announce a collaboration agreement with Astellas Pharma, a global life sciences company.

The BSA developed by Hyundai Mobis consists of a battery management system (BMS), hardware consisting of a fire extinguishing ...

Trump confirms tariffs remain on electronics amid exemptions. Upcoming investigations may target semiconductors & supply ...